<DOC>
	<DOCNO>NCT01671059</DOCNO>
	<brief_summary>This non-interventional study evaluate use efficacy tocilizumab ( RoActemra/Actemra ) participant moderate severe rheumatoid arthritis . Eligible participant initiate tocilizumab treatment accord approve label follow 6 month .</brief_summary>
	<brief_title>A Non-Interventional Study Evaluating Rheumatoid Arthritis Participants Treated With Tocilizumab ( RoActemra/Actemra )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult participant , &gt; /= 18 year age Moderate severe rheumatoid arthritis accord revise ( 1987 ) American College Rheumatology ( ACR ) criteria Participants treat physician make decision commence tocilizumab treatment ( accordance local label ) ; could include participant received tocilizumab treatment within 8 week prior enrollment visit Participants receive tocilizumab 8 week prior enrollment visit Participants previously receive tocilizumab clinical trial compassionate use Treatment investigational agent within 4 week ( 5 halflives investigational agent , whichever long ) start treatment tocilizumab History autoimmune disease joint inflammatory disease rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>